Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

Beware the rise of ‘Marxist nationalism’. As Australian ex-PM Kevin Rudd explains in his new study, On Xi Jinping, China has imperial dreams ...

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...

I’ve been writing and editing technology content for over seven years, most recently as part of PCMag's software team. I am responsible for the creativity, education, operating system ...

Investing in a new kitchen is a significant decision. To help you choose the best kitchen company, we've meticulously tested and researched leading kitchen brands. Our experts evaluated 19 kitchen ...

Our lens reviews offer detailed information on sharpness, distortion, bokeh, and all the other important factors that go into making a lens great. Our reviews give you all the information you need ...

Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached over $13bn in global sales, which affirms its commercial advantage and sets a milestone ...

The use of Sanofi’s Dupixent in atopic dermatitis has set a high benchmark for competitors within the space. Credit: marishkaSm via Shutterstock. Sanofi’s participation at the JP Morgan 43rd Annual ...

Sanofi’s chief executive Paul Hudson discussed the success of Dupixent (dupilumab)and the remarkable achievement of over $13 billion in global sales in 2024, highlighting its commercial advantage and ...

Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers a promising outlook, prompting a BUY rating. EYLEA HD's success mitigates biosimilar competition ...